Aciphex

Type: Product

Name: Aciphex

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Is Johnson & Johnson Heading Off The Patent Cliff?

Home » Blogs » Patent expiration is one of the number one reasons for pharma companies' revenue deterioration. The industry giant, Johnson & Johnson (JNJ), is expected to witness revenue loss of $2.27 billion due to two patent expirations in 2013. Aciphex, ... [Published BioPortfolio - May 13 2013]

Entities: Johnson & Johnson, Patent, Drugs, Aciphex, Waldenström macroglobulinemia

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Digestive issues common with advancing age

It was four years ago that Aventura attorney Ivy Ginsberg had her first attack of acid reflux, and the memory of the painful experience is still fresh.She had just finished a big dinner of steak, fries and garlicky chimichurri sauce and was getting ready ... [Published Miami Herald - Apr 29 2013]

Entities: Constipation, reflux, Acid, gastroenterologist

First reported Apr 17 2013 - Updated Apr 17 2013 - 2 reports

Johnson & Johnson

Strong first quarter for J&J thanks to new products

Johnson & Johnson has posted an 8.5% increase in sales for the first quarter, helped by a strong showing at its pharmaceuticals division.Group net income came in at $3.50 billion, down 10.6% compared to the like, year-earlier period which was affected ... [Published Pharma Times - Apr 17 2013]

Entities: Johnson & Johnson, infliximab, Xarelto

First reported Mar 28 2013 - Updated Mar 28 2013 - 1 reports

FDA Food & Drug Administration

Eisai's paediatric formulation Aciphex Sprinkle gets US FDA nod for treatment of GERD

The US Food and Drug Administration (FDA) has approved Eisai Inc's paediatric formulation Aciphex Sprinkle (rabeprazole sodium, product name in Japan: Pariet) delayed release capsules 5 mg and 10 mg for the treatment of gastroesophageal reflux disease ... [Published PharmaBiz - Mar 28 2013]

Entities: Aciphex, FDA Food & Drug Administration, Eisai Co Ltd

First reported Mar 28 2013 - Updated Mar 28 2013 - 1 reports

Eisai Co Ltd

FDA clears Eisai gastroesophageal reflux disease therapy for children

The US FDA has cleared Eisai's ACIPHEX Sprinkle (rabeprazole sodium) as 12-week gastroesophageal reflux disease (GERD) therapy for use in children between one to eleven years age.The approval was based on positive data from multicenter, double-blind trial ... [Published Pharmaceutical Business Review - Mar 28 2013]

Entities: gastroesophageal reflux disease, Eisai Co Ltd, FDA Food & Drug Administration, rabeprazole

First reported Dec 12 2012 - Updated Dec 12 2012 - 1 reports

FDA grants additional marketing exclusivity for Eisai's GERD drug

Eisai's Aciphex (rabreprazole sodium) has met the FDA's Written Request requirements for pediatric exclusivity in US. ... [Published PBR - News - Dec 12 2012]

Entities: Drugs, Aciphex, Sodium

First reported Dec 03 2012 - Updated Dec 03 2012 - 1 reports

US FDA grants priority review status for Eisai's NDA for proton-pump inhibitor, Aciphex

The US Food and Drug Administration (FDA) has accepted Eisai's New Drug Application (NDA) for a new sprinkle capsule formulation (5mg and 10mg) of the proton-pump inhibitor AcipHex (rabeprazole sodium, product name in Japan: Pariet) for the healing and ... [Published PharmaBiz - Dec 03 2012]

Entities: Aciphex, Acid, Duodenal ulcer, Helicobacter Pylori, gastroesophageal reflux disease

Quotes

...is the first time in a decade and its first global one ever that the company is indulging in a corporate re-brand ad campaign following recall of "millions of bottles and packages of Tylenol, Benadryl, Motrin and other over-the-counter medicines." One wonders whether the re-branding exercise was needed especially as it carries a risk of reminding customers of the mistakes committed earlier...

Johnson & Johnson: An Investment In A Healthcare Conglomerate That Cannot Go Wrong [Published Seeking Alpha - May 13 2013]

...Vivus Board has proven to be poor stewards of shareholder capital," commented Sam Colin, M D , Senior Managing Director at FMC and a Board nominee. "Qsymia's potential is substantial. However, Vivus has badly mismanaged the Qsymia launch, and neither the recent REMS modification nor the addition of a new director will cure the root cause of the failure. Vivus and its shareholders deserve a Board worthy of Qsymia. Our slate of six highly qualified nominees has the independence, the experience, and the plan to fix the Company before time runs out."

First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivu [Published Daily Finance - May 01 2013]

"We are pleased that Vivus has chosen to add a new director with large pharma experience and one who has been associated with a long-standing shareholder. It is a sad statement that multiple failed attempts to launch Qsymia, an obesity drug with blockbuster potential, were clearly not enough to prod this Board into action. It was only in response to FMC's campaign to elect our six highly qualified nominees that the current Board has chosen to act."

First Manhattan Comments on Addition to Vivus' Board of Directors [Published Zecco - May 01 2013]

...He also mentioned the improvement of the OTC unit, which has suffered thousands of recalls over the last few years, saying "we continue to make progress in returning a reliable supply of high qualityquality products" . J&J confirmed its earnings guidance for full-year 2013 of $5.35-$5.45 per share, excluding special items

Strong first quarter for J&J thanks to new products [Published Pharma Times - Apr 17 2013]

More Content

sort by: Date \| Relevance
Johnson & Johnson: An Investment In A Healthcar... [Published Seeking Alpha - May 13 2013]
Is Johnson & Johnson Heading Off The Patent Cliff? [Published BioPortfolio - May 13 2013]
Johnson & Johnson: Banking On Industry Revival [Published Seeking Alpha - May 09 2013]
3 Bio Companies Facing The Patent Cliff [Published Seeking Alpha - May 07 2013]
First Manhattan Files Preliminary Proxy Materia... [Published Daily Finance - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Equities.com - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Benzinga.com - May 01 2013]
VIVUS, INC.: First Manhattan Comments on Additi... [Published 4 Traders - May 01 2013]
First Manhattan Comments on Addition to Vivus' ... [Published Zecco - May 01 2013]
Digestive issues common with advancing age [Published Miami Herald - Apr 29 2013]
Strong first quarter for J&J thanks to new prod... [Published Pharma Times - Apr 17 2013]
OTC recovery helps J&J in first-quarter [Published PMLive - Apr 17 2013]
Eisai's paediatric formulation Aciphex Sprinkle... [Published PharmaBiz - Mar 28 2013]
FDA clears Eisai gastroesophageal reflux diseas... [Published Pharmaceutical Business Review - Mar 28 2013]
FDA Approves ACIPHEX® Sprinkle™ (Rabeprazole So... [Published PR Newswire: Policy & Public Interest - Mar 27 2013]
ACIPHEX (Rabeprazole Sodium) Tablet, Coated [Br... [Published DailyMed Drug Label Updates for the last seven ... - Feb 05 2013]
ACIPHEX (Rabeprazole Sodium) Tablet, Coated [Br... [Published DailyMed Drug Label Updates for the last seven ... - Feb 02 2013]
ACIPHEX (Rabeprazole Sodium) Tablet, Coated [Br... [Published DailyMed Drug Label Updates for the last seven ... - Jan 29 2013]
FDA grants additional marketing exclusivity for... [Published PBR - News - Dec 12 2012]
Eisai Granted Additional Six Month U.S. Marketi... [Published PR Newswire: Policy & Public Interest - Dec 11 2012]
US FDA grants priority review status for Eisai'... [Published PharmaBiz - Dec 03 2012]
FDA Accepts AcipHex® (rabeprazole sodium) Pedia... [Published PR Newswire: Health - Nov 30 2012]
Antacids can cause Bone Fracture [Published Topnews.in - May 27 2010]